

Index

Acquired amyloid neuropathy overview, 144 clinical features, 144 diagnostic evaluation, 144 electrodiagnostic evaluation, 144 management, 144 pathology, 144	Acute motor axonal neuropathy (AMAN) overview, 113 clinical features, 113 diagnostic evaluation, 113 electrodiagnostic evaluation, 113t21.1 management, 113 pathology, 113	radial nerve neuropathies clinical features, 79 diagnostic evaluation, 79 management, 79
Acute immune neuropathies overview, 103 acute inflammatory demyelinating polyradiculoneuropathy (AIDP) (<i>See</i> Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)) acute motor and sensory axonal neuropathy (AMSAN) (<i>See</i> Acute motor and sensory axonal neuropathy (AMSAN)) acute motor axonal neuropathy (AMAN) (<i>See</i> Acute motor axonal neuropathy (AMAN))	Alcohol-related neuropathy overview, 149 clinical features, 149 diagnostic evaluation, 149 pathology, 149	Axonal damage, 9–10 Axons, 7–8
Bickerstaff brainstem encephalopathy (BEE) (<i>See</i> Bickerstaff brainstem encephalopathy (BEE)) Fisher syndrome (FS) (<i>See</i> Fisher syndrome (FS)) Guillain-Barré syndrome (GBS) (<i>See</i> Guillain-Barré syndrome (GBS))	Amiodarone-associated neuropathy overview, 153 clinical features, 153 diagnostic evaluation, 153 management, 153 pathology, 153	Bariatric surgery-associated neuropathy overview, 145 clinical features, 145 electrodiagnostic evaluation, 145 laboratory evaluation, 145 management, 145 pathology, 145
Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) overview, 109 clinical features, 109 diagnostic evaluation, 110 electrodiagnostic evaluation, 110–11 management, 111 motor nerve conduction criteria, 109t19.1 pathology, 109	Anatomy. <i>See</i> Peripheral nerve anatomy; <i>specific condition</i>	Bickerstaff brainstem encephalopathy (BEE) overview, 105, 115 clinical features, 115 diagnostic evaluation overview, 115–16 electrodiagnostic evaluation, 116 laboratory evaluation, 116 management, 116 pathology, 115
Acute motor and sensory axonal neuropathy (AMSAN) overview, 112 clinical features, 112 diagnostic evaluation, 112 electrodiagnostic evaluation, 112t20.1 management, 112 pathology, 112	Ankle, tibial nerve neuropathies clinical features, 95 electrodiagnostic evaluation, 95 imaging evaluation, 95–96 management, 96	Biopsies overview, 37 amyloid biopsies, 37 autonomic testing, 37–38 nerve biopsies, 37, 118 skin biopsies, 37 vasculitic neuropathy, 118
	Anterior interosseous syndrome, 61 Anticonvulsant drugs, 203 Antidepressant drugs, 203	Bortezomib-associated neuropathy overview, 152 clinical features, 152 diagnostic evaluation, 152 management, 152 pathology, 152
	Arm median nerve neuropathies clinical features, 59 diagnostic evaluation, 59 management, 59 radial nerve neuropathies clinical features, 79 diagnostic evaluation, 79–80 management, 80	B deficiency-related neuropathy. <i>See</i> Colbamin (B12) deficiency-related neuropathy
	Arsenic-related neuropathy overview, 150 clinical features, 150 diagnostic evaluation, 150 management, 150 pathology, 150	Cancer chemotherapeutic drug-associated neuropathy overview, 151 bortezomib overview, 152 clinical features, 152 diagnostic evaluation, 152 management, 152 pathology, 152
	Axilla median nerve neuropathies clinical features, 58 diagnostic evaluation, 58 management, 59	

Index

- Cancer chemotherapeutic
 drug-associated neuropathy
 (*cont.*)
 platinum-containing drugs
 overview, 151
 clinical features, 151
 diagnostic evaluation, 151
 management, 151
 pathology, 151
 taxanes
 overview, 152
 clinical features, 152
 diagnostic evaluation, 152
 management, 152
 pathology, 152
 vinca alkaloid drugs
 overview, 151
 clinical features, 152
 diagnostic evaluation, 152
 management, 152
 pathology, 152
- CANOMAD, 130
- Carpal tunnel syndrome, 61t8.3, 64–68
 overview, 61
 clinical features, 61–62
 double-crush syndrome and, 45–46
 electrodiagnostic evaluation, 62–68
 management, 66–67
 median-ulnar nerve anastomoses
 and, 64–68
 risk factors, 61t8.3
 sensory and motor nerve
 conduction studies, 62t8.4
 ultrasound imaging, 65
- Celiac disease-associated neuropathy
 overview, 168
 clinical features, 168
 diagnostic evaluation, 168
 management, 168–69
 pathology, 168
- Charcot Marie Tooth neuropathies.
See Hereditary neuropathies
- Chronic immune demyelinating
 polyradiculoneuropathy
 (CIDP)
 overview, 123
 clinical features, 123–24
 diabetic neuropathies and, 142
 diagnostic evaluation
 overview, 124
 electrodiagnostic evaluation,
 124–25
 laboratory evaluation, 125–26
 MRI imaging, 125
 ultrasound imaging, 125
 EFNS/PNS criteria, 125t24.2
 management
 overview, 126
 corticosteroids, 126
 immunoglobulin, 126
 other options, 127
 plasmapheresis, 126–27
 treatment outcome, 127
 pathology, 123
 refractory CIDP, disease-modifying
 treatments, 201
 syndromes
 overview, 129
 CANOMAD, 130
 POEMS syndrome, 130
 variants
 overview, 129
 distal acquired demyelinating
 symmetric neuropathy
 (DADS), 129
 focal limb variant, 129
 motor variant, 129
 sensory variant, 129
- Chronic immune peripheral
 neuropathies
 overview, 121
 chronic immune demyelinating
 polyradiculoneuropathy
 (CIDP) (*See* Chronic
 immune demyelinating
 polyradiculoneuropathy
 (CIDP))
 multifocal acquired demyelinating
 sensory and motor neuropathy
 (MADSAM) (*See* Multifocal
 acquired demyelinating
 sensory and motor neuropathy
 (MADSAM))
 multifocal motor neuropathy
 with conduction block (*See*
 Multifocal motor neuropathy
 with conduction block)
- Clinical approach
 overview, 17
 clinical examination, 18–20
 clinical history, 17–19
 electrodiagnostic
 examination, 20–21
 epidemiological consideration, 21
 reports, 21–22
- Clinical features. *See specific condition*
- CMT1 (autosomal dominant), 179
 CMT2 (autosomal dominant), 179
 CMT4 (autosomal recessive), 179
 CMTX (x-linked), 179
- Colbamin (B12) deficiency-related
 neuropathy
 overview, 160
 clinical features, 160
 electrodiagnostic evaluation, 160
 laboratory evaluation, 160
 management, 160
 pathology, 160
- Colchicine-associated neuropathy
 overview, 153
 clinical features, 153
 electrodiagnostic evaluation, 153
 laboratory evaluation, 153
 management, 153
 pathology, 153
 Collateral reinnervation, 15
 Compression-entrapment
 neuropathies, 12
 Corticosteroids, 200
 Critical illness-associated neuropathy
 overview, 147
 clinical features, 147
 diagnostic evaluation, 147
 electrodiagnostic evaluation, 147–48
 management, 148
 pathology, 147
- Devices to assist function, 195
- Diabetic neuropathies
 overview, 139
 acute painful neuropathy associated
 with insulin treatment, 142
 CIDP and, 142
 diabetic painful neuropathy
 overview, 142
 clinical features, 142
 diagnostic evaluation, 142
 laboratory evaluation, 142
 management, 142
 pathology, 142
 diabetic symmetric polyneuropathy
 (DSPN)
 overview, 139
 clinical features, 140
 diagnostic evaluation, 140–41
 electrodiagnostic evaluation,
 140–41
 laboratory evaluation, 140–41
 management, 141
 pathology, 139
 types of, 139t28.1
- Diagnostic evaluation. *See also specific
 condition*
 overview, 33
 autonomic tests, 33
 biopsies
 overview, 37
 amyloid biopsies, 37
 autonomic testing, 37–38
 nerve biopsies, 37, 118
 skin biopsies, 37
 vasculitic neuropathy, 118
 electrodiagnostic evaluation (*See*
 Electrodiagnostic evaluation)
 imaging evaluation (*See* Imaging
 evaluation)
 laboratory evaluation, 34–37
 (*See also specific condition*)
 nerve and muscle imaging
 overview, 34

- magnetic resonance neurography, 34
- ultrasound imaging, 34
- overall diagnostic test yield, 38
- screening of laboratory tests
 - overview, 34–35
 - B12 and metabolites, 35
 - diabetes and metabolic syndrome, 35
 - immunoglobulin testing, 35
- special laboratory tests
 - overview, 35
 - folate deficiency, 36
 - ganglioside antibody tests, 36
 - genetic testing for hereditary neuropathies, 36–37
 - hepatic function tests, 36
 - renal failure and creatinine level, 36
 - rheumatologic tests, 35–36
 - spinal fluid analysis, 36
 - thyroid function tests, 35
 - Vitamin B6 excess, 36
- ultrasound imaging (*See* Ultrasound imaging)
- Distal acquired demyelinating symmetric neuropathy (DADS), 129
- Dominant intermediate CMT, 179
- Double-crush syndrome, 45–46
- Drug-associated neuropathy
 - overview, 151
 - amiodarone (*See* Amiodarone-associated neuropathy)
 - bortezomib (*See* Bortezomib-associated neuropathy)
 - cancer chemotherapeutic drugs (*See* Cancer chemotherapeutic drug-associated neuropathy)
 - colchicine (*See* Colchicine-associated neuropathy)
 - HIV drugs, 154
 - nitrofurantoin (*See* Nitrofurantoin-associated neuropathy)
 - platinum-containing drugs (*See* Platinum-containing drug-associated neuropathy)
 - pyridoxine (*See* Pyridoxine-associated neuropathy)
 - taxanes (*See* Taxane-associated neuropathy)
 - thalidomide (*See* Thalidomide-associated neuropathy)
 - vinca alkaloid drugs (*See* Vinca alkaloid drug-associated neuropathy)
- Drug treatment of peripheral neuropathies. *See* Pharmacologic treatment of peripheral neuropathies
- Elbow
 - median nerve neuropathies
 - overview, 59
 - clinical features, 59
 - diagnostic evaluation, 59
 - management, 59
 - radial nerve neuropathies
 - clinical features, 80–81
 - diagnostic evaluation, 81
 - management, 81
 - ulnar nerve neuropathies
 - overview, 70–71
 - clinical features, 71–72
 - electrodiagnostic evaluation, 72–74
 - management, 74–75
 - ultrasound imaging, 74
- Electrodiagnostic evaluation.
 - See also specific condition*
 - overview, 23
 - cautions in interpretation
 - overview, 29
 - low SNAPs, 30–31
 - measurement errors, 30
 - mismarked SNAP and CMAP waveforms, 31
 - recording electrode position, 29–30
 - temperature, 29
 - understimulation or overstimulation, 30
 - very slow or low CMAP potentials, 30
 - interpretation, 31
 - necessity of, 31
 - needle EMG, 31
 - nerve conduction tests, 23–25
 - anatomic and physiologic features, 24t4.1
 - SNAP and CMAP nerve conduction metrics, 2526t4.2
 - nerve pathology assessment
 - overview, 25
 - primary axonal loss, 25–26
 - primary conduction block, 27–29
 - primary demyelination, 26–27
 - reports, 31
 - studies, 33
 - testing strategies, 23
- Endoneurium, 8
- Environmental toxin-related neuropathy
 - overview, 149
 - alcohol (*See* Alcohol-related neuropathy)
 - arsenic (*See* Arsenic-related neuropathy)
 - lead (*See* Lead-related neuropathy)
- Epineurium, 8
- European Federation of Neurological Societies (EFNS), CIDP criteria, 125t24.2
- Evaluation approach
 - overview, 1
 - clinical approach (*See* Clinical approach)
 - diagnostic evaluation (*See* Diagnostic evaluation)
 - electrodiagnostic evaluation (*See* Electrodiagnostic evaluation)
 - peripheral nerve anatomy (*See* Peripheral nerve anatomy)
 - peripheral nerve pathology (*See* Peripheral nerve pathology)
- Exercise, 195–96
- Fabry disease-associated neuropathy
 - overview, 185
 - clinical features, 185
 - diagnostic evaluation, 185
 - management, 185
 - pathology, 185
- Fascicles, 7
- Femoral nerve neuropathies
 - overview, 91
 - anatomy, 91
 - clinical features, 91
 - diagnostic evaluation
 - overview, 92
 - imaging evaluation, 92
 - management, 92
 - pathology, 91
 - root innervation, 91f13.1
- Fibular/peroneal nerve neuropathies
 - overview, 83
 - anatomy, 83
 - knee
 - clinical features, 84
 - electrodiagnostic evaluation, 84–85
 - management, 85
 - ultrasound imaging, 85
 - pathology, 83–84
 - root innervation, 84t11.1
- Fisher syndrome (FS)
 - overview, 105, 115
 - clinical features, 115
 - diagnostic evaluation
 - overview, 115–16
 - electrodiagnostic evaluation, 116
 - laboratory evaluation, 116
 - management, 116
 - pathology, 115

Index

- Focal conduction block, 11–12
- Folic acid deficiency-related neuropathy
 overview, 160
 clinical features, 161
 diagnostic evaluation, 161
 management, 161
 pathology, 160
- Forearm, median nerve neuropathies
 overview, 59
 anterior interosseous syndrome, 61
 pronator teres syndrome, 60
- Gluten sensitivity-related neuropathy
 overview, 168
 clinical features, 168
 diagnostic evaluation, 168
 management, 168–69
 pathology, 168
- Guillain-Barré syndrome (GBS)
 overview, 105
 associated antibodies, 106t18.2
 Bickerstaff brainstem
 encephalopathy (BEE)
 (See Bickerstaff brainstem
 encephalopathy (BEE))
 clinical features, 105–6
 diagnostic evaluation, 106
 electrodiagnostic evaluation, 106–7
 Fisher syndrome (FS) (See Fisher
 syndrome (FS))
 geographic distribution, 107t18.3
 management, 107
 pathology, 106
 variants of, 105
- Guyon's canal, 75
- Hand, median nerve neuropathies
 clinical features, 67
 diagnostic evaluation, 67
 management, 68
- Hereditary amyloid neuropathy
 overview, 183
 clinical features, 183–84
 diagnostic evaluation, 184
 electrodiagnostic evaluation, 184
 management, 184
 pathology, 183
- Hereditary neuropathies
 overview, 173, 175
 associated mutations, 176t42.1
 clinical features, 175–77
 CMT1 (autosomal dominant), 179
 CMT2 (autosomal dominant), 179
 CMT4 (autosomal recessive), 179
 CMTX (x-linked), 179
 dominant intermediate CMT, 179
 electrodiagnostic evaluation, 178–79
 Fabry disease-associated neuropathy
 (See Fabry disease-associated
 neuropathy)
- hereditary amyloid neuropathy (See
 Hereditary amyloid neuropathy)
 HSN/HSAN, 180
 laboratory evaluation, 177–78
 management, 178–79
 pathology, 175
 porphyria-associated neuropathies
 (See Porphyria-associated
 neuropathies)
 with predisposition to pressure
 palsies (autosomal dominant),
 12, 179–80
- Hip, sciatic nerve neuropathies
 clinical features, 88
 diagnostic evaluation, 88
 management, 88
- HIV-associated neuropathy. *See*
 Human immunodeficiency
 virus-associated neuropathy
- HSN/HSAN, 180
- Human immunodeficiency
 virus-associated neuropathy
 overview, 156
 clinical features, 156
 electrodiagnostic evaluation, 156
 HIV drug-associated
 neuropathy, 154
 laboratory evaluation, 156
 management, 156
 pathology, 156
- Idiopathic microvasculitis, 50
- Imaging evaluation
 femoral nerve neuropathies, 92
 multifocal motor neuropathy with
 conduction block, 132
 piriformis syndrome, 89
 plexopathies, 52
 radiculopathies, 44
 sciatic nerve neuropathies, 89
 tibial nerve neuropathies, 94
 ankle, 95–96
 knee, 94
 ultrasound imaging (See Ultrasound
 imaging)
- Immunoglobulin
 CIDP management, 126
 intravenous immune globulin, 200–1
 screening of laboratory tests, 35
 subcutaneous immune globulin, 201
- Inflammatory bowel
 disease-associated
 neuropathy, 189
- Intraepidermal nerve terminals, 8
- Intravenous immune globulin, 200–1
- Knee
 fibular/peroneal nerve neuropathies
 clinical features, 84
 electrodiagnostic evaluation, 84–85
- management, 85
 ultrasound imaging, 85
- tibial nerve neuropathies
 clinical features, 93
 electrodiagnostic evaluation, 94
 imaging evaluation, 94
 management, 95
- Laboratory evaluation, 34–37. *See also*
specific condition
- Lateral femoral cutaneous nerve
 neuropathies
 overview, 97
 anatomy, 97
 clinical features, 97
 electrodiagnostic evaluation, 98
 management, 98
 pathology, 97–98
- Lead-related neuropathy
 overview, 149
 clinical features, 149
 diagnostic evaluation, 149
 management, 149–50
 pathology, 149
- Length-dependent axonal loss, 12–13
- Length-dependent polyneuropathies
 overview, 135
 acquired amyloid neuropathy (See
 Acquired amyloid neuropathy)
 alcohol-related neuropathy (See
 Alcohol-related neuropathy)
 amiodarone-associated neuropathy
 (See Amiodarone-associated
 neuropathy)
 arsenic-related neuropathy (See
 Arsenic-related neuropathy)
 bariatric surgery-associated
 neuropathy (See Bariatric
 surgery-associated neuropathy)
 cancer chemotherapeutic
 drug-associated neuropathy
 (See Cancer chemotherapeutic
 drug-associated neuropathy)
 celiac disease-associated neuropathy
 (See Celiac disease-associated
 neuropathy)
 clinical features, 137
 colbamin (B12) deficiency-related
 neuropathy (See Colbamin
 (B12) deficiency-related
 neuropathy)
 colchicine-associated neuropathy
 (See Colchicine-associated
 neuropathy)
 critical illness-associated
 neuropathy (See Critical
 illness-associated neuropathy)
 diabetic neuropathies (See Diabetic
 neuropathies)
 electrodiagnostic evaluation, 137–38

- folic acid deficiency-related neuropathy (*See* Folic acid deficiency-related neuropathy)
- general features, 137
- gluten sensitivity-related neuropathy (*See* Gluten sensitivity-related neuropathy)
- HIV drug-associated neuropathy, 154
- human immunodeficiency virus-associated neuropathy (*See* Human immunodeficiency virus-associated neuropathy)
- lead-related neuropathy (*See* Lead-related neuropathy)
- leprous neuropathy (*See* Leprous neuropathy)
- Lyme disease-associated neuropathy (*See* Lyme disease-associated neuropathy)
- nitrofurantoin-associated neuropathy (*See* Nitrofurantoin-associated neuropathy)
- paraneoplastic sensory neuropathy (*See* Paraneoplastic sensory neuropathy)
- pathology, 137
- pyridoxine-associated neuropathy (*See* Pyridoxine-associated neuropathy)
- systemic inflammatory response syndrome (SIRS), 147
- thalidomide-associated neuropathy (*See* Thalidomide-associated neuropathy)
- uremic neuropathy (*See* Uremic neuropathy)
- Leprous neuropathy
 - overview, 158
 - clinical features, 158
 - electrodiagnostic evaluation, 158–59
 - imaging evaluation, 159
 - laboratory evaluation, 158
 - management, 159
 - pathology, 158
- Lyme disease-associated neuropathy
 - overview, 170
 - clinical features, 170
 - electrodiagnostic evaluation, 171
 - laboratory evaluation, 170–71
 - management, 171
 - pathology, 170
- Management of peripheral neuropathies.
 - See also specific condition*
 - overview, 193
 - devices to assist function, 195
 - disease-modifying treatments
 - overview, 198–200
 - corticosteroids, 200
 - intravenous immune globulin, 200–1
 - non-pharmacologic treatment, 202
 - plasma exchange, 201
 - refractory CIDP, 201
 - subcutaneous immune globulin, 200–1
 - exercise, 195–96
 - neuropathy assessment
 - overview, 197
 - assessment scales, 197–99
 - nerve conduction studies, 198
 - strength assessment, 197–98
 - non-pharmacologic treatment, 202
 - painful neuropathy treatment
 - overview, 201
 - pathology, 201–2
 - treatment principles, 202
 - patient education, 195
 - pharmacologic treatment
 - overview, 197, 202
 - anticonvulsant drugs, 203
 - antidepressant drugs, 203
 - opioid drugs, 203
 - other drugs, 203
 - physical care, 195
- Median nerve neuropathies
 - overview, 57
 - anatomy, 57
 - arm
 - clinical features, 59
 - diagnostic evaluation, 59
 - management, 59
 - axilla
 - clinical features, 58
 - diagnostic evaluation, 58
 - management, 59
 - elbow
 - overview, 59
 - clinical features, 59
 - diagnostic evaluation, 59
 - management, 59
 - forearm
 - overview, 59
 - anterior interosseous syndrome, 61
 - pronator teres syndrome, 60
 - hand
 - clinical features, 67
 - diagnostic evaluation, 67
 - management, 68
 - pathology, 57–58
 - root innervation, 59t8.1
 - wrist
 - overview, 61
 - clinical features, 61–62
 - electrodiagnostic studies, 62–68
 - management, 66–67
 - media-ulnar nerve anastomoses, 64–68
 - sensory and motor nerve conduction studies, 62t8.4
 - ultrasound imaging, 65
- Media-ulnar nerve anastomoses, 64–68
- Microvasculitis, 13–14
- Mononeuropathies
 - overview, 55
 - femoral nerve neuropathies (*See* Femoral nerve neuropathies)
 - fibular/peroneal nerve neuropathies (*See* Fibular/peroneal nerve neuropathies)
 - lateral femoral cutaneous nerve neuropathies (*See* Lateral femoral cutaneous nerve neuropathies)
 - median nerve neuropathies (*See* Median nerve neuropathies)
 - radial nerve neuropathies (*See* Radial nerve neuropathies)
 - saphenous nerve neuropathies (*See* Saphenous nerve neuropathies)
 - sciatic nerve neuropathies (*See* Sciatic nerve neuropathies)
 - sural nerve neuropathies (*See* Sural nerve neuropathies)
 - tibial nerve neuropathies (*See* Tibial nerve neuropathies)
 - ulnar nerve neuropathies (*See* Ulnar nerve neuropathies)
- Motor unit, 8
- MRI imaging for CIDP, 125
- Multifocal acquired demyelinating sensory and motor neuropathy (MADSAM)
 - overview, 131, 133
 - clinical features, 133
 - electrodiagnostic evaluation, 133
 - laboratory evaluation, 133
 - management, 133
- Multifocal motor neuropathy with conduction block
 - overview, 131
 - clinical features, 131
 - diagnostic evaluation
 - overview, 131–32
 - electrodiagnostic evaluation, 132
 - imaging evaluation, 132
 - laboratory evaluation, 132
 - management, 132
 - pathology, 131
- Multifocal neuropathies with conduction block, 12
- Myelin, 7
- Myelin damage, 9–10
- Needle EMG, 31
- Nerve and muscle imaging
 - overview, 34

Index

- Nerve and muscle imaging (*cont.*)
 magnetic resonance neurography, 34
 ultrasound imaging, 34
- Nerve conduction tests, 23–25
 anatomic and physiologic features, 24t4.1
 SNAP and CMAP nerve conduction metrics, 25t4.2
- Nerve damage, 9–15
- Nerve pathology assessment
 overview, 25
 primary axonal loss, 25–26
 primary conduction block, 27–29
 primary demyelination, 26–27
- Nerve roots and plexuses, 4–6
- Neurosarcoidosis
 overview, 189
 clinical features, 189
 electrodiagnostic evaluation, 189–90
 laboratory evaluation, 189
 management, 190
 pathology, 189
- Nitrofurantoin-associated neuropathy
 overview, 153
 clinical features, 154
 diagnostic evaluation, 154
 management, 154
 pathology, 153
- Nodal damage, 10–11
- Node of Ranvier, 7
- Nutritional deficiency-related neuropathies
 cobalamin (B12) (*See* Cobalamin (B12) deficiency-related neuropathy)
 folic acid (*See* Folic acid deficiency-related neuropathy)
- Opioid drugs, 203
- Paraneoplastic sensory neuropathy
 overview, 162
 clinical features, 163
 electrodiagnostic evaluation, 163
 laboratory evaluation, 163
 management, 163
 pathology, 162–63
- Pathology. *See* Peripheral nerve pathology; *specific condition*
- Patient education, 195
- Pelvis, sciatic nerve neuropathies
 clinical features, 88–89
 clinical tests, 89
 electrodiagnostic evaluation, 89
 imaging evaluation, 89
 management, 89
- Perineurium, 8
- Peripheral nerve anatomy. *See also specific condition*
 overview, 3
 axons, 7–8
 endoneurium, 8
 epineurium, 8
 fascicles, 7
 gross anatomic arrangement, 3–7
 intraepidermal nerve terminals, 8
 microscopic anatomic arrangement, 7–8
 motor unit, 8
 myelin, 7
 nerve roots and plexuses, 4–6
 nerve variability
 overview, 5–6
 accessory fibular/peroneal nerve, 7
 Martin-Gruber anastomosis, 6–7
 node of Ranvier, 7
 perineurium, 8
 peripheral nerves, 5
 somatic motor nerves, 3–4
 somatic sensory nerves, 3–4
 variant innervation patterns, 7
- Peripheral nerve pathology. *See also specific condition*
 overview, 9
 axonal damage, 9–10
 collateral reinnervation, 15
 compression-entrapment neuropathies, 12
 focal conduction block, 11–12
 length-dependent axonal loss, 12–13
 microvasculitis, 13–14
 multifocal neuropathies with conduction block, 12
 myelin damage, 9–10
 nerve damage, 9–15
 nodal damage, 10–11
 primary demyelinating polyneuropathy, 14–15
- Peripheral nerves, 5
- Peripheral Nerve Society (PNS), CIDP criteria, 125t4.2
- Pharmacologic treatment of peripheral neuropathies
 overview, 202
 anticonvulsant drugs, 203
 antidepressant drugs, 203
 opioid drugs, 203
 other drugs, 203
- Physical care, 195
- Piriformis syndrome
 clinical features, 88–89
 clinical tests, 89
 electrodiagnostic evaluation, 89
 imaging evaluation, 89
 management, 89
- Plasma exchange, 201
- Platinum-containing drug-associated neuropathy
 overview, 151
 clinical features, 151
 diagnostic evaluation, 151
 management, 151
 pathology, 151
- Plexopathies
 overview, 47
 anatomy, 47–51
 clinical evaluation, 50–52
 electrodiagnostic evaluation, 52
 idiopathic microvasculitis, 50
 imaging evaluation, 52
 innervation patterns, 47–51
 management, 52–53
 pathology, 47–50
 thoracic outlet syndrome, 48
- POEMS syndrome, 130
- Porphyria-associated neuropathies
 overview, 181
 acute porphyrias, 181
 clinical features, 181–82
 electrodiagnostic evaluation, 182
 laboratory evaluation, 182
 management, 182
 metabolic abnormalities, 182t43.1
 pathology, 181
- Primary demyelinating polyneuropathy, 14–15
- Pronator teres syndrome, 60
- Proximal neuropathies
 overview, 41
 plexopathies (*See* Plexopathies)
 radiculopathies (*See* Radiculopathies)
- Pyridoxine-associated neuropathy
 overview, 154
 clinical features, 154
 diagnostic evaluation, 154
 management, 154
 pathology, 154
- Radial nerve neuropathies
 overview, 78
 anatomy, 78–79
 arm
 clinical features, 79
 diagnostic evaluation, 79–80
 management, 80
 axilla
 clinical features, 79
 diagnostic evaluation, 79
 management, 79
 elbow
 clinical features, 80–81
 diagnostic evaluation, 81
 management, 81
 pathology, 78–79
 root innervation, 79t10.1
 wrist
 overview, 81
 diagnostic evaluation, 81
 management, 81

- Radiculopathies
 - overview, 43
 - anatomy, 43–44
 - clinical features, 43–44
 - double-crush syndrome, 45–46
 - electrodiagnostic evaluation, 44–45
 - frequency, 43
 - imaging evaluation, 44
 - management, 46
 - muscle, nerve and root innervation, 43–44
 - pathology, 43
- Rare condition-associated neuropathies
 - overview, 187
 - inflammatory bowel disease, 189
 - neurosarcoidosis (*See* Neurosarcoidosis)
 - rheumatologic disease, 190
 - thyroid disease (*See* Thyroid disease-associated neuropathy)
- Rheumatologic disease-associated neuropathy, 190
- Saphenous nerve neuropathies
 - overview, 101
 - anatomy, 101
 - clinical features, 101
 - diagnostic evaluation, 101–2
 - management, 102
 - pathology, 101–2
- Sciatic nerve neuropathies
 - overview, 87
 - anatomy, 87
 - hip
 - clinical features, 88
 - diagnostic evaluation, 88
 - management, 88
 - pathology, 87–88
 - pelvis
 - clinical features, 88–89
 - clinical tests, 89
 - electrodiagnostic evaluation, 89
 - imaging evaluation, 89
 - management, 89
 - piriformis syndrome
 - clinical features, 88–89
 - clinical tests, 89
 - electrodiagnostic evaluation, 89
 - imaging evaluation, 89
 - management, 89
 - root innervation, 87f12.1
- Screening of laboratory tests
 - overview, 34–35
 - B12 and metabolites, 35
 - diabetes and metabolic syndrome, 35
 - immunoglobulin testing, 35
- Small fiber neuropathy
 - overview, 164
 - clinical features, 164
 - diagnostic evaluation, 164
 - management, 164–65
 - pathology, 13–14, 164
- Somatic motor nerves, 3–4
- Somatic sensory nerves, 3–4
- Subcutaneous immune globulin, 201
- Sural nerve neuropathies
 - overview, 99
 - anatomy, 99
 - clinical features, 100
 - diagnostic evaluation, 100
 - management, 100
 - pathology, 99–100
- Systemic inflammatory response syndrome (SIRS), 147
- Taxane-associated neuropathy
 - overview, 152
 - clinical features, 152
 - diagnostic evaluation, 152
 - management, 152
 - pathology, 152
- Thalidomide-associated neuropathy
 - overview, 152
 - clinical features, 152
 - diagnostic evaluation, 153
 - management, 153
 - pathology, 152
- Thoracic outlet syndrome, 48
- Thyroid disease-associated neuropathy
 - overview, 190
 - clinical features, 190
 - electrodiagnostic evaluation, 190
 - laboratory evaluation, 190
 - management, 190
 - pathology, 190
- Tibial nerve neuropathies
 - overview, 93
 - anatomy, 93
 - ankle
 - clinical features, 95
 - electrodiagnostic evaluation, 95
 - imaging evaluation, 95–96
 - management, 96
 - knee
 - clinical features, 93
 - electrodiagnostic evaluation, 94
 - imaging evaluation, 94
 - management, 95
 - pathology, 93
 - root innervation, 94f14.1
- Ulnar nerve neuropathies
 - overview, 70
 - anatomy, 70–72
 - elbow
 - overview, 70–71
 - clinical features, 71–72
 - electrodiagnostic evaluation, 72–74
 - management, 74–75
 - ultrasound imaging, 74
 - pathology, 70–73
 - root innervation, 72t9.1
 - wrist
 - overview, 75
 - causes, 75
 - deep motor branch, 75
 - electrodiagnostic evaluation, 76
 - Guyon's canal, 75
 - management, 76
 - superficial terminal branch, 75
 - ultrasound imaging, 76
- Ultrasound imaging
 - carpal tunnel syndrome, 65
 - CIDP, 125
 - fibular/peroneal nerve neuropathies, 85
 - median nerve neuropathies, 65
 - nerve and muscle imaging
 - generally, 34
 - ulnar nerve neuropathies
 - elbow, 74
 - wrist, 76
- Uncertain association-related neuropathies
 - overview, 187
 - inflammatory bowel disease, 189
 - neurosarcoidosis (*See* Neurosarcoidosis)
 - rheumatologic disease, 190
 - thyroid disease (*See* Thyroid disease-associated neuropathy)
- Uremic neuropathy
 - overview, 166
 - acute neuropathy, 166
 - clinical features, 166
 - diagnostic evaluation
 - overview, 166
 - electrodiagnostic evaluation, 166–67
 - laboratory evaluation, 166
 - management, 167
 - pathology, 166
- Vasculitic neuropathy
 - overview, 117
 - clinical features, 117
 - electrodiagnostic evaluation, 118
 - laboratory evaluation, 118
 - management, 118–19
 - microvasculitis, 13–14
 - nerve biopsy, 118
 - pathology, 13, 117
- Vinca alkaloid drug-associated neuropathy
 - overview, 151
 - clinical features, 152
 - diagnostic evaluation, 152
 - management, 152
 - pathology, 152

Index

Wrist	sensory and motor nerve	overview, 75
median nerve neuropathies	conduction studies, 62t8.4	causes, 75
overview, 61	ultrasound imaging, 65	deep motor branch, 75
clinical features, 61–62	radial nerve neuropathies	electrodiagnostic evaluation, 76
electrodiagnostic studies, 62–68	overview, 81	Guyon’s canal, 75
management, 66–67	diagnostic evaluation, 81	management, 76
media-ulnar nerve	management, 81	superficial terminal branch, 75
anastomoses, 64–68	ulnar nerve neuropathies	ultrasound imaging, 76